Benefits and Satisfaction with Apremilast Treatment in Patients with Psoriasis Affecting the Genital Area: Secondary Analysis of the APPRECIATE Study.

IF 3.5 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2025-03-01 Epub Date: 2025-02-19 DOI:10.1007/s13555-025-01360-y

Neuza da Silva Burger, Kathy V Tran, Methodios Typou, Rachel Sommer, David Neasham, Myriam Cordey, Matthias Augustin

{"title":"Benefits and Satisfaction with Apremilast Treatment in Patients with Psoriasis Affecting the Genital Area: Secondary Analysis of the APPRECIATE Study.","authors":"Neuza da Silva Burger, Kathy V Tran, Methodios Typou, Rachel Sommer, David Neasham, Myriam Cordey, Matthias Augustin","doi":"10.1007/s13555-025-01360-y","DOIUrl":null,"url":null,"abstract":"Introduction: Plaque-type psoriasis affects the genital area in 7-42% of patients, and can impose significant quality of life (QoL) impairments. In this case, systemic treatment is recommended regardless of the affected body surface area. This real-world study compared treatment effects and patient-reported outcomes (PROs) between patients with and without genital lesions, undergoing apremilast treatment for 6 ± 1 months.Methods: Secondary analyses were conducted using data from the observational, retrospective, cross-sectional APPRECIATE study. Adult patients with plaque-type psoriasis who initiated apremilast during the previous 6 ± 1 months were consecutively recruited in seven European countries between May 2016 and November 2019. At the time of study inclusion (T1), clinical and PROs were assessed by physician/patient questionnaires. Baseline data were collected retrospectively from medical records.Results: This study included 482 patients: 108 with genital psoriasis (GenPso+) and 374 without genital lesions (GenPso-). The GenPso+ group had higher disease burden at baseline. For patients receiving ongoing treatment at T1, there was significant improvement in disease severity and marginally significant improvement in QoL impairments, independent of genital involvement. Satisfaction with medication and patient benefits also did not differ between groups.Conclusion: This study further established the value of apremilast as a systemic treatment for patients with psoriasis, including those with genital involvement.Trial registration: The APPRECIATE study was registered at https://clinicaltrials.gov/ with the number NCT02740218.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"681-695"},"PeriodicalIF":3.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909379/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01360-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Plaque-type psoriasis affects the genital area in 7-42% of patients, and can impose significant quality of life (QoL) impairments. In this case, systemic treatment is recommended regardless of the affected body surface area. This real-world study compared treatment effects and patient-reported outcomes (PROs) between patients with and without genital lesions, undergoing apremilast treatment for 6 ± 1 months.

Methods: Secondary analyses were conducted using data from the observational, retrospective, cross-sectional APPRECIATE study. Adult patients with plaque-type psoriasis who initiated apremilast during the previous 6 ± 1 months were consecutively recruited in seven European countries between May 2016 and November 2019. At the time of study inclusion (T1), clinical and PROs were assessed by physician/patient questionnaires. Baseline data were collected retrospectively from medical records.

Results: This study included 482 patients: 108 with genital psoriasis (GenPso+) and 374 without genital lesions (GenPso-). The GenPso+ group had higher disease burden at baseline. For patients receiving ongoing treatment at T1, there was significant improvement in disease severity and marginally significant improvement in QoL impairments, independent of genital involvement. Satisfaction with medication and patient benefits also did not differ between groups.

Conclusion: This study further established the value of apremilast as a systemic treatment for patients with psoriasis, including those with genital involvement.

Trial registration: The APPRECIATE study was registered at https://clinicaltrials.gov/ with the number NCT02740218.

查看原文本刊更多论文

阿普米司特治疗影响生殖器区域的银屑病患者的益处和满意度：APPRECIATE研究的二次分析

斑块型银屑病在7-42%的患者中影响生殖器区域，并可造成显著的生活质量（QoL）损害。在这种情况下，无论受影响的体表面积如何，都建议进行全身治疗。这项现实世界的研究比较了有和没有生殖器病变的患者在接受阿普米司特治疗6±1个月后的治疗效果和患者报告的结果（PROs）。方法：采用观察性、回顾性、横断面的APPRECIATE研究资料进行二次分析。在2016年5月至2019年11月期间，在7个欧洲国家连续招募了在过去6±1个月内开始使用阿普米司特的斑块型银屑病成年患者。在纳入研究时（T1），通过医师/患者问卷对临床和PROs进行评估。从医疗记录中回顾性收集基线数据。结果：本研究纳入482例患者：108例伴有生殖器银屑病（GenPso+）， 374例无生殖器病变（GenPso-）。GenPso+组在基线时的疾病负担较高。对于T1时接受持续治疗的患者，疾病严重程度有显著改善，生活质量受损有轻微改善，与生殖器受累无关。两组患者对药物治疗和患者获益的满意度也没有差异。结论：本研究进一步确立了阿普雷米司特作为银屑病患者全身治疗的价值，包括那些累及生殖器的患者。试验注册：APPRECIATE研究在https://clinicaltrials.gov/注册，注册号为NCT02740218。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.